JP2021501803A - 近視の進行を制御し且つ／又は減少させるための医薬組成物 - Google Patents

近視の進行を制御し且つ／又は減少させるための医薬組成物 Download PDF

Info

Publication number
JP2021501803A
JP2021501803A JP2020544068A JP2020544068A JP2021501803A JP 2021501803 A JP2021501803 A JP 2021501803A JP 2020544068 A JP2020544068 A JP 2020544068A JP 2020544068 A JP2020544068 A JP 2020544068A JP 2021501803 A JP2021501803 A JP 2021501803A
Authority
JP
Japan
Prior art keywords
treatment
ophthalmic
myopia
eye
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020544068A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021501803A5 (enExample
Inventor
セオドア コロネオ ミナス
セオドア コロネオ ミナス
ジョング モニカ
ジョング モニカ
ラジャゴパル サンカリドゥルグ パドマジャ
ラジャゴパル サンカリドゥルグ パドマジャ
レオ スミス サード アール
レオ スミス サード アール
カウル アマンディープ
カウル アマンディープ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2021501803A publication Critical patent/JP2021501803A/ja
Publication of JP2021501803A5 publication Critical patent/JP2021501803A5/ja
Priority to JP2023135274A priority Critical patent/JP2023179418A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020544068A 2017-11-03 2018-11-02 近視の進行を制御し且つ／又は減少させるための医薬組成物 Pending JP2021501803A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023135274A JP2023179418A (ja) 2017-11-03 2023-08-23 近視の進行を制御し且つ／又は減少させるための医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762581112P 2017-11-03 2017-11-03
US62/581,112 2017-11-03
PCT/AU2018/051187 WO2019084621A1 (en) 2017-11-03 2018-11-02 Pharmaceutical compositions for controlling and/or reducing the progression of myopia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023135274A Division JP2023179418A (ja) 2017-11-03 2023-08-23 近視の進行を制御し且つ／又は減少させるための医薬組成物

Publications (2)

Publication Number Publication Date
JP2021501803A true JP2021501803A (ja) 2021-01-21
JP2021501803A5 JP2021501803A5 (enExample) 2021-12-16

Family

ID=66331107

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020544068A Pending JP2021501803A (ja) 2017-11-03 2018-11-02 近視の進行を制御し且つ／又は減少させるための医薬組成物
JP2023135274A Pending JP2023179418A (ja) 2017-11-03 2023-08-23 近視の進行を制御し且つ／又は減少させるための医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023135274A Pending JP2023179418A (ja) 2017-11-03 2023-08-23 近視の進行を制御し且つ／又は減少させるための医薬組成物

Country Status (10)

Country Link
US (1) US20200345633A1 (enExample)
EP (1) EP3703691A4 (enExample)
JP (2) JP2021501803A (enExample)
KR (1) KR20200088824A (enExample)
CN (3) CN118384160A (enExample)
AU (1) AU2018359013A1 (enExample)
CA (1) CA3081593A1 (enExample)
SG (1) SG11202004005RA (enExample)
TW (1) TW201932104A (enExample)
WO (1) WO2019084621A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3763280A1 (de) * 2019-07-11 2021-01-13 Carl Zeiss Vision International GmbH Bestimmung einer veränderung eines refraktionsfehlers eines auges
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
CN116785286A (zh) * 2020-10-10 2023-09-22 远大生命科学(武汉)有限公司 戊乙奎醚在治疗或预防视力损伤性眼部疾病中的用途
TW202317132A (zh) * 2021-06-11 2023-05-01 澳大利亞商布萊恩荷登視覺協會 眼用組合物及/或用於老花眼、瞳孔放大及/或眼部不適管理之方法
CN119139472A (zh) * 2024-09-26 2024-12-17 温州医科大学附属眼视光医院 腺苷信号阻滞剂在制备治疗弱视和改善视觉可塑性的药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710051B1 (en) * 1997-01-06 2004-03-23 Klaus Trier Aps Screening method
WO2012161655A1 (en) * 2011-05-23 2012-11-29 Singapore Health Services Pte Ltd Composition and/or method for reducing and/or preventing myopia progression comprising atropine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BG61430B1 (bg) * 1994-03-23 1997-08-29 Иван ХРИСТОВ антиастматично лекарствено средство
AU2100795A (en) * 1994-06-06 1996-01-04 Warner-Lambert Company Non-sedating allergy sinus medication
US5574044A (en) * 1994-10-27 1996-11-12 Merck & Co., Inc. Muscarine antagonists
US20110104083A1 (en) * 2009-10-30 2011-05-05 Intratus, Inc. Methods and cosmetic preparations for the sustained delivery of therapeutic agents to the eye
JP5993620B2 (ja) * 2011-06-01 2016-09-14 ロート製薬株式会社 点眼剤
WO2016172712A2 (en) * 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710051B1 (en) * 1997-01-06 2004-03-23 Klaus Trier Aps Screening method
WO2012161655A1 (en) * 2011-05-23 2012-11-29 Singapore Health Services Pte Ltd Composition and/or method for reducing and/or preventing myopia progression comprising atropine

Also Published As

Publication number Publication date
KR20200088824A (ko) 2020-07-23
SG11202004005RA (en) 2020-05-28
JP2023179418A (ja) 2023-12-19
CN111787920A (zh) 2020-10-16
EP3703691A1 (en) 2020-09-09
CN118384160A (zh) 2024-07-26
CN118403054A (zh) 2024-07-30
AU2018359013A1 (en) 2020-05-21
CA3081593A1 (en) 2019-05-09
TW201932104A (zh) 2019-08-16
WO2019084621A1 (en) 2019-05-09
US20200345633A1 (en) 2020-11-05
EP3703691A4 (en) 2021-07-28

Similar Documents

Publication Publication Date Title
US20250049761A1 (en) Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
JP2023179418A (ja) 近視の進行を制御し且つ／又は減少させるための医薬組成物
CN116850183A (zh) 用于治疗近视的方法和药物组合物
CN115634226B (zh) 一种采用长春西汀治疗近视的方法
CN116981457A (zh) 有效预防、控制和根除老花眼的低浓度剂量的协同眼科组合物
HK40039952A (en) Pharmaceutical compositions for controlling and/or reducing the progression of myopia
Galeana Prospective Interventional Non-Comparative Non-Randomized Clinical Study of A Topical Synergic Compound to Mitigate Presbyopia Effects
HK40086794A (zh) 一种采用长春西汀治疗近视的方法
HK40086794B (zh) 一种采用长春西汀治疗近视的方法
NZ623037B2 (en) Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
HK1198426B (en) Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211027

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211027

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221011

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230308

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230425